Povidone-iodine reduces contamination rate

Article

A recent prospective study has shown that the repetitive irrigation of povidone-iodine of 0.25% significantly lowered bacterial contamination rate in the anterior chamber after cataract surgery.

A recent prospective study has shown that the repetitive irrigation of povidone-iodine of 0.25% significantly lowered bacterial contamination rate in the anterior chamber after cataract surgery.

Dr Hiroyuki Shimada and Dr Takayuki Hattori, Department of Ophthalmology, School of Medicine, Nihon University, Tokyo, Japan, investigated the use of povidone-iodine to reduce bacteria in patients with cataracts.

The investigation involved 404 consecutive eyes - 202 eyes were filled with infusion liquid (group A) and 202 eyes were treated using povidone-iodine of 0.25%. The fluids from the anterior chamber were collected at the start and end of surgery to measure the iodide ion concentration. Bacteriologic culture was carried out using the ocular surface fluid after lid speculum placement, and anterior chamber fluid after surgery. The measurement of corneal endothelial cell density was conducted before and after surgery, using a specular microscope.

The rate of bacterial detection in ocular surface liquid demonstrated a small difference between groups A (5.5%) and B (6.0%). However, the reduction rate in anterior chamber fluid was significantly greater in group B.

To conclude, the repetitive irrigation of the anterior chamber lowered bacterial contamination to a great extent after cataract surgery.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.